Advertisement
The Body: The Complete HIV/AIDS Resource
Sign up for free e-mail updates!The Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV All Topics Relating to HIV
This Month in HIV: A Podcast of Critical News in HIV
  • E-mail E-Mail
  • Comments Comments
  • Printer Friendly Printable Single-Page
  • Glossary Glossary
  • Bookmark and Share Share

May 2008 Podcast -- Top 10 HIV Stories of the Past Year: An Interview With David Wohl, M.D. -- By Bonnie Goldman

Multimedia Toolbox
Listen to Podcast (56 min.)
  

  • Download Podcast

  • Read Interview Summary

  • Podcast FAQ

  • Subscribe to This Month in HIV!


Previous Podcasts

Advertisement
 < Prev  |  1  |  2  |  3  |  4  |  5  |  6 

Runners Up


  1. Cooper D, Gatell J, Rockstroh J, et al, for the BENCHMRK-1 Study Group. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, Calif. Abstract 105aLB.
  2. Steigbigel R, Kumar P, Eron J, et al, for the BENCHMRK-2 Study Group. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, Calif. Abstract 105bLB.
  3. Gulick RM, van der Ryst E, Lampiris H, et al. Efficacy and safety of once-daily (QD) compared with twice-daily (BID) maraviroc plus optimized background therapy (OBT) in treatment-experienced patients infected with CCR5-tropic-HIV-1: 24-week combined analysis of the MOTIVATE 1 and 2 studies. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB116LB.
  4. van der Ryst E, Cooper D, Konourina I, et al. Efficacy of maraviroc in combination with at least one other potent new antiretroviral drug: 24-week combined analysis of the MOTIVATE 1 and 2 studies. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB115LB.
  5. Madruga JV, Cahn P, Grinsztejn B, et al, on behalf of the DUET-1 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. July 7, 2007;370(9581):29-38.
  6. Lazzarin A, Campbell T, Clotet B, et al, on behalf of the DUET-2 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. July 7, 2007;370(9581):39-48.
  7. Clotet B, Bellos N, Molina J-M, et al, on behalf of the POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. April 7, 2007;369(9568):1169-1178.
  8. DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Ill. Abstract H-718b.
    View slides: Download PowerPoint
  9. Markowitz M, Nguyen B-Y, Gotuzzo E, et al, and the Protocol 004 Part II Study Team. Rapid onset and durable antiretroviral effect of raltegravir (MK-0518), a novel HIV-1 integrase inhibitor, as part of combination ART in treatment HIV-1 infected patients: 48-week data. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract TUAB104.
    View slides: Download PowerPoint
  10. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WESS104.
    View slides: Download PowerPoint
  11. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis. November 15, 2007;45(10):1369-1374.
  12. Egger M. Outcomes of ART in resource-limited and industrialized countries. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, Calif. Abstract 62.
  13. Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003. In: Program and abstracts of the National HIV Prevention Conference; June 12-15, 2005; Atlanta, Ga. Abstract T1-B1101.
  14. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. September 22, 2006;55(RR14):1-17.
  15. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. April 26, 2007;356(17):1723-1735.
  16. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. November 30, 2006;355(22):2283-2296.
  17. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. November 20, 2003;349(21):1993-2003.
  18. National Center for Chronic Disease Prevention and Health Promotion's Office on Smoking and Health. Adult cigarette smoking in the United States: current estimates. Centers for Disease Control and Prevention Web site. Updated November 2007.
  19. Sabin C, Worm S, Weber R, et al, and the D:A:D Study Group. Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D:A:D study. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Mass. Abstract 957c.
  20. NIAID modifies HIV antiretroviral treatment study. Bethesda, Md: U.S. National Institute of Allergy and Infectious Diseases; February 28, 2008.
  21. Harris NS, Fowler MG, Sansom SL, Ruffo N, Lampe MA. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001. Am J Obstet Gynecol. September 2007;197(3):S33-S41.
  22. Bujan L, Hollander L, Coudert M, et al, for the CREAThE network. Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE network. AIDS. September 2007;21(14):1909-1914.
  23. James A, Johann-Liang R. Increased rate and severity of abacavir-associated hypersensitivity reaction in randomized controlled clinical trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Mass. Abstract 835.
    View poster: Download PDF
  24. Mallal S, Phillips E, Carosi G, et al. PREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030). In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WESS101.
  25. Saag M, Balu R, Brachman P, et al. High sensitivity of HLA-B*5701 in whites and blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR). In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEAB305.
    View slides: Download PowerPoint
  26. Mallal S, Phillips E, Carosi G, et al, for the PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. February 7, 2008;358(6):568-579.
  27. Immunizations are discontinued in two HIV vaccine trials. Bethesda, Md.: National Institute of Allergy and Infectious Diseases (NIAID); September 21, 2007.
  28. Robertson M, Mehrotra D, Fitzgerald D, et al. Efficacy results from the STEP study (Merck V520 Protocol 023/HVTN 502): a phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef trivalent vaccine. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Mass. Abstract 88LB.
    View slides: Download PDF
  29. Chase M, Mckay B. Upward revision of U.S. AIDS cases likely. Wall Street Journal. December 1, 2007:A3.
  30. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2005. Cases of HIV infection and AIDS in the United States and dependent areas, 2005. Rev. Ed. Atlanta, Ga.: Centers for Disease Control and Prevention; June 2007. Volume 17.
  31. Colfax GN, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht FM. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS. January 11, 2007;21(2):239-341.
  32. Hser Y-I, Evans E, Huang Y-C. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat. January 2005;28(1):77-85.
  33. Mansergh G, Purcell DW, Stall R, et al. CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions. Public Health Rep. March-April 2006;121(2):127-132.
  34. Das-Douglas M, Colfax G, Moss AR, Bangsberg DR, Hahn JA. Tripling of methamphetamine/amphetamine use among homeless and marginally housed persons, 1996-2003. J Urban Health [serial online]. December 27, 2007.
  35. Drumright LN, Little SJ, Strathdee SA, et al. Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection. J Acquir Immune Defic Syndr. November 1, 2006;43(3):344-350.
  36. Lohse N, Hansen A-BE, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. January 16, 2007;146(2):87-95.
  37. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. July 7, 2007;370(9581):59-67.
  38. Kissin DM, Zapata L, Yorick R, et al. HIV seroprevalence in street youth, St. Petersburg, Russia. AIDS. November 2007;21(17):2333-2340.
  39. Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization (WHO). AIDS epidemic update. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; December 2007.
  40. Gross J. AIDS patients face downside of living longer. New York Times. January 6, 2008: Section A:1.
  41. Desquilbet L, Jacobson LP, Fried LP, et al, for the Multicenter AIDS Cohort Study. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. November 2007;62(11):1279-1286.
  42. Effros RB. Telomeres and HIV disease. Microbes Infect. January 2000;2(1):69-76.
  43. Borthwick NJ, Bofill M, Gombert WM, et al. Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28- T cells. AIDS. April 1994;8(4):431-441.
  44. Global HIV prevalence has levelled off; AIDS is among the leading causes of death globally and remains the primary cause of death in Africa. The Joint United Nations Programme on HIV/AIDS; November 20, 2007.
 < Prev  |  1  |  2  |  3  |  4  |  5  |  6 

Copyright © 2008 Body Health Resources Corporation. All rights reserved. Podcast disclaimer


Reader Comments:

Comment by: Sima (Dsm) Sat., Jan. 24, 2009 at 11:00 am EST
Thanx for the wonderfull web site.i now know where to get different information about AIDS/HIV.

Comment by: Priscillar (South Africa, Johannesburg) Thu., Nov. 20, 2008 at 10:49 am EST
I was diagnosed last year, 2007, with a CD4 of 59. Now I am at 550, taking Truvada and Stoctrin. What are my chances of opportunistic diseases, and toxicities? I need to be linked with a friend in SA.

Comment by: azazhu (Ethiopia) Tue., Oct. 7, 2008 at 10:06 am EDT
that is very itnteresting

Comment by: jim (alaska) Tue., Oct. 7, 2008 at 2:12 am EDT
i get the body regularly in e-mail and I am so thankful to all the wonderful doctors that contibute. I found out I had AIDS when I was hospitalised in 2000 with pml encephalitis and thank god for great doctors and great medicines i am alive to write this and i am am doing quite well. my past doctors whom i have kept n contact with in oregon are amazed. i was paralyzed on the right side of my body and they told my mother i would not survive the week. now i am a truck driver driving big semi's! People, get tested. If applicable, get on meds and PLEASE do not miss any doses. i say this from the bottom of my heart! You can e-mail me at willow444@msn.com. have a wonderful life! GET TESTED!!!!! Thank you again wonderful doctors!!!!!!!

Comment by: caco (florida) Mon., Sep. 22, 2008 at 11:11 am EDT
Will we ever find a cure for HIV?

Comment by: runing.outof.time (vaal) Wed., Sep. 10, 2008 at 7:22 am EDT
we r dieying. where or when is the cure

Comment by: simone (Rosebud,SD) Tue., Sep. 2, 2008 at 12:42 pm EDT
I'm working to get the Native American people to get tested on the Reservation we have no testing. I'm working to collaborate with IHS to start testing I'm with the CHR Program. The hardest part is trying to get the people to get tested. I'm going to do the best I can to get them tested. I just wanted to let people know that their is a problem getting people tested everywhere.

Comment by: lashawna Mon., Aug. 11, 2008 at 8:46 pm EDT
i think people really need to understand what sex is. too many people think it's ok to have unprotected sex when it is not ok. if you are going to do something with someone, wrap it up please. be the smarter person. that goes for straight people and gay people. get it together people! life is too short, please do not make it shorter.

Comment by: jerry morales Thu., Jul. 31, 2008 at 1:33 pm EDT
I have a comment for dissidence 101, you weren't to concerened about vaccine success when you became infected and these drugs do seem to be keeping me alive. So bravo for the new drugs. I'm on Prezista and Isentress and celebrate their arrival. I'm sorry life doesn't seem as rosey for you.

Comment by: Casey Fri., Jul. 18, 2008 at 12:14 pm EDT
I was wondering if you knew where to find information on how to join a certain study group of individuals with HIV+ in their states?

Comment by: Innocent Fri., Jul. 11, 2008 at 9:10 am EDT
I have recently been diagnosed HIV+ but now i have hope that i can live longer but i've got a problem with FLU & Tonsils help....S.A

Comment by: Jason Mon., Jul. 7, 2008 at 7:16 pm EDT
I read that CDC predicts that if someone is positive less than four months that they can eliminate the virus from the body (with meds) within an average of 7.7 years. Is this true?

Comment by: rami Mon., Jul. 7, 2008 at 3:28 pm EDT
Thank you very much for this energy you are putting into these podcasts / reviews. i find this so importnat. this gives much hope and info. Thank you!

Comment by: wam Sat., Jul. 5, 2008 at 12:49 pm EDT
Hi Ezekiel Otieno where are you in Kenya. I am also positive living in U.K detected about 9 mths ago single mum of three. You can email me at nan.sa08@hotmail.com

Comment by: Gideon Lawal Mon., Jun. 30, 2008 at 9:34 am EDT
Well am kinda new to this well. i lost my brother to this disease. right now the last time i check my status i was positive too and then my cd4 count is 375 and am still on oi. i need a friend from Europe and USA and anywhere in the world to help pass through this hard time right now am having stomach pain and headache.. here is my email: gideon080seyi@yahoo.com Hope to hear from you soon Later Seyi

Comment by: mickery Sun., Jun. 29, 2008 at 2:06 pm EDT
That's a great interview that everyone (whether positive or negative) should read.

Comment by: dorcas Thu., Jun. 26, 2008 at 8:28 am EDT
doc.a big well done 4 d enlightenment.it goes a long way to give hope and encouragement to all the infected.its a therapy.hiv is a fundamental right and not a disease that needs to be adhered to.thanks

Comment by: abdalla Tue., Jun. 24, 2008 at 3:21 am EDT
very exciting!

Comment by: Robert Tue., Jun. 3, 2008 at 1:42 pm EDT
Dear Drs. at "The Body" Keep up the good work! As you say all the time, there are great drugs out there but prevention is key!

Comment by: bruno Sun., Jun. 1, 2008 at 8:40 pm EDT
god bless us all. stay strong people.

Comment by: jason Sat., May. 31, 2008 at 10:33 am EDT
are there some of those drugs here in the philippines and how much its cost?

Comment by: hilary Wed., May. 28, 2008 at 6:30 pm EDT
i have just found out my wonderfull nephew is HIV. Am so upset, my world has came crashing down. Thank God i can read positive stories. i can only pray he will outlive me. This happens to other familes not mine or so i thought. feel so ashamed. i thought HIV was AIDS I'm learning, however we all pretend it is not happening. i pray for a cure.

Comment by: araceli villafania Tue., May. 27, 2008 at 2:07 pm EDT
very good info

Comment by: TEDDY Thu., May. 15, 2008 at 9:05 pm EDT
Good job, but we need drugs that you could take once a month,any possibility? I know the pharmaceutical companies will frown over this as it will make volumes on profitable

Comment by: johnk Wed., May. 14, 2008 at 12:55 am EDT
What a smart, sharp overview! I too think the plethora of new interesting drugs is the story of the year. They have given me lots of hope as I've undetectable for the first time in 15 years! HIV medicine has made such strides. I'm one lucky man!

Comment by: John morse Sun., May. 11, 2008 at 10:42 pm EDT
I was diagnosed with HiV at age 70! I am currently enrolled in a trail 96 week study for HIV naieve people. I am taking MK-0518 (or Placebo) Efavirenz (or placebo) and Truvada. within three months of taking the medications My viral load was undetectable and CD was up to 415 from 275! I have been on this program for a year now.

Comment by: dissidence101 Sun., May. 11, 2008 at 10:22 pm EDT
That's just simply amazing that the biggest story of the whole year is "THERE'S MORE DRUGS". Gezze. I have a better one. How about and to the dismay of researchers, Merck's v520 complete and utter vaccine trial failure?

Comment by: Noni Sat., May. 10, 2008 at 3:20 pm EDT
I started treatment in 2003 with CD4 of 8.I was on d4t, 3tc. I experienced loss of fats in hips and butt and changed to azt. Problem is i always worry about what if it doesnt work because in S.A we have only limited (2) regimens available. Are we S.A allowed to have or access these plenty of meds available in U.S.A and other countries? If so how do you access them? Worried in South Africa

Comment by: ezekiel otieno Sat., May. 10, 2008 at 9:10 am EDT
this website has given me a lot of strength.Through this I've learnt that i can live long enough than the seven years since i knew my status and i'm not alone. I'm requesting this website to connect me one person living positively in Europe or Asia. I am from Kenya.

Comment by: Carole Ricks Wed., May. 7, 2008 at 7:45 pm EDT
Hello Everyone; I would like to say how happy I am for all that have found their meds to work and they are doing great, Thank God for that, because He is always looking out for us all the time. I lost my brother to Hiv/Aids last year because he didn't and wouldn't seek treatment until it was too late. I miss him very much and I also have another brother who is Hiv positive as well. He is keeping up with his doctor's visits and taking care of himself. Please know that there are programs out there that can help you if you are sick. Don't wait! Seek help right away and remember that knowledge is power. God bless you all.

Comment by: Dr. Elizabeth Mwanukuzi Wed., May. 7, 2008 at 10:20 am EDT
It is very interesting to note that the problem of late diagnosis is not limited to resource poor countries but what is particularly challenging to us in Africa is the poor accessibility of care and treatment facilities for rural communities because of poverty and poor travel intfrastructure

Comment by: A AL YAZOURY Wed., May. 7, 2008 at 10:02 am EDT
THANK U GUYS FOR THIS GEART WEBSITE,THANK U VERY MUCH DOC FOR YOUR GREAT EFFORTS, I SUGGEST HIV TESTING FOR EVERY PERSON ONCE THEY ARE IN THE PROCESS OF GETTING ENSURACE CARD SO THIS WILL MAKE IT MORE EASY FOR EARLY DETECTION FOR THE VIRUS AND EARLY HELP AND BETEER PROGNOSIS, GOD BLESS U ALL.

Comment by: Akan Ituk Wed., May. 7, 2008 at 9:33 am EDT
A major problem with the HIV pandemic is that most folks is yet to come in terms with the reality. They "believe" they are uninfectable and as such need not to go for HIV screening. It is not until HIV is succesfully demystified, social immunization will not be achieved.

Comment by: AMAL Wed., May. 7, 2008 at 7:46 am EDT
THANKS DOC FOR YOUR WORK, PRAYERS FROM THE HEART FOR ALL THE POZs TO GET WELL SOON. IT'S A MATTER OF TIME, ONCE YOU R IN THE ACCEPTANCE STAGE YOU CAN LIVE NORMALLY. THANKS

Comment by: Brown Family Foundation Tue., May. 6, 2008 at 9:26 pm EDT
This article was very informative. Our organization promotes HIV Prevention and Detection. We've established a program called "Sisters Can We Talk". This program consist of panel discussions and small group sessions dealing with the subject of HIV and AIDS. We utilize local organizations to provide testing at each event. This confirms that more opportunities are needed to present testing.

Comment by: Stuart Lee Carlson Tue., May. 6, 2008 at 5:46 pm EDT
Doc, thanks for your good work! I've been poz for over 18 years now, and can say with confidence the hiv bug is a manageable disease. Reason for writing is this: Fat has been stripped from my arms, legs, and butt. If it would help, I am quite able to give you the litany of all the drug regimens between start to the present. In summary first drug was AZT in 1992, when CD4 was 290. Currently I am taking Isentress, Aprivus, Norvir, and Epzicom and my CD4 is 770, wowee ! and VL is und. For all I know, it seems to be a metabolic puzzle, and fortunately, no facial wasting, thank God. Please advise. Cheers! Lee

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Google search results. Be careful when providing personal information!)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: